|
Sep 30
|
Wall Street Analysts Think AbbVie (ABBV) Is a Good Investment: Is It?
|
|
Sep 30
|
15 Best Dividend Stocks for Lifelong Passive Income
|
|
Sep 29
|
Is AbbVie Inc.'s (NYSE:ABBV) ROE Of 78% Impressive?
|
|
Sep 27
|
15 Unhealthiest Countries in Latin America
|
|
Sep 27
|
ABBV's Newly Added Parkinson's Disease Drug Meets Second Study Goal
|
|
Sep 27
|
AbbVie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer
|
|
Sep 27
|
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
|
|
Sep 27
|
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
|
|
Sep 27
|
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
|
|
Sep 27
|
AbbVie’s $8.7bn Parkinson’s disease drug shines in Phase III trial
|
|
Sep 26
|
AbbVie Says Pivotal Trial For Parkinson's Candidate Meets Its Primary Goal In Patients With Early Disease
|
|
Sep 26
|
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
|
|
Sep 26
|
AbbVie's Parkinson's disease drug meets main goal in late-stage trial
|
|
Sep 26
|
AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
|
|
Sep 26
|
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
|
|
Sep 26
|
AbbVie’s RINVOQ shows promise in two Phase III atopic dermatitis trials
|
|
Sep 25
|
AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Sep 25
|
Exploring Three High Growth Tech Stocks in the United States
|
|
Sep 25
|
New Analysis Demonstrates the Efficacy of RINVOQ® (upadacitinib) in Atopic Dermatitis with Varying Degrees of Severity in Head and Neck Involvement
|
|
Sep 24
|
Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns
|